Resistance Without Record: The Surveillance Failures Allowing Antibiotic-Resistant Pathogens to Move Freely Through the American Meat Supply

A Recognized Threat With an Unresolved Regulatory Response

Antimicrobial resistance has been described by the World Health Organization as one of the defining public health challenges of the twenty-first century. In the United States, the Centers for Disease Control and Prevention estimates that more than 2.8 million antibiotic-resistant infections occur annually, resulting in over 35,000 deaths. A meaningful proportion of those infections trace their origins—directly or through horizontal gene transfer—to the agricultural use of antibiotics in livestock production.

Yet despite this recognized causal pathway, the regulatory architecture governing antimicrobial resistance surveillance in the American meat supply remains fragmented, narrowly scoped, and structurally inadequate for the scale of the problem it purports to address.

This is not a question of scientific uncertainty. The mechanisms by which antibiotic use in food-producing animals selects for resistant bacterial strains, which then enter the food chain and the broader environment, are well established in the peer-reviewed literature. What remains deficient is the institutional will to translate that scientific understanding into comprehensive surveillance policy.

What Current Testing Does and Does Not Capture

The National Antimicrobial Resistance Monitoring System, known as NARMS, operates as a collaborative effort among the FDA, CDC, and USDA, and represents the primary federal infrastructure for tracking resistance patterns in foodborne bacteria. Established in 1996, NARMS monitors resistance in a defined set of enteric bacteria—principally Salmonella, Campylobacter, E. coli, and Enterococcus—isolated from retail meat samples, human clinical cases, and slaughterhouse ceca.

This architecture, while meaningful, leaves substantial surveillance gaps. NARMS does not systematically monitor for the full spectrum of resistance genes present in livestock-associated bacterial communities. It does not comprehensively track mobile genetic elements—plasmids and transposons—that can transfer resistance determinants between bacterial species entirely independent of direct pathogen transmission. And it operates on sample sizes that, while statistically useful for trend identification, are insufficient for the granular regional or production-system analysis needed to identify emerging resistance hotspots before they reach clinical significance.

Equally important is what NARMS does not require of industry. Unlike pharmaceutical manufacturers, who operate under post-market surveillance obligations, commercial meat producers are not required to conduct or report internal resistance monitoring as a condition of market access. The surveillance burden falls entirely on the public health system, operating downstream from the point of resistance generation.

The Regulatory Jurisdictional Divide

The division of regulatory authority between the USDA and FDA introduces an additional layer of structural incoherence. The USDA's Food Safety and Inspection Service holds primary authority over meat, poultry, and egg products, while the FDA oversees antimicrobial drug approvals for veterinary use. This bifurcation means that the agency responsible for approving antibiotic use in livestock—the FDA—has limited direct authority over the surveillance of resistance outcomes in meat products, which falls to the USDA.

The practical consequence is a system in which the regulatory body best positioned to impose upstream restrictions on antibiotic use cannot compel the downstream surveillance data that would demonstrate the effects of its own policy decisions. This jurisdictional architecture was not designed to facilitate comprehensive resistance monitoring; it reflects a historical division of agricultural and pharmaceutical oversight that predates the modern understanding of antimicrobial resistance dynamics.

The FDA's 2013 Guidance Document 213, which phased out the use of medically important antibiotics for growth promotion in food animals, represented a meaningful step. However, the guidance retained broad permissions for therapeutic and disease prevention uses—categories that, in practice, account for the majority of antibiotic volume used in livestock production and that continue to exert selection pressure on resistant populations.

The European Regulatory Contrast

The contrast with European regulatory frameworks is instructive. The European Union's 2019 Veterinary Medicinal Products Regulation, which came into force in January 2022, introduced binding restrictions on prophylactic antibiotic use in food animals, prohibited the use of certain critically important antibiotics in livestock entirely, and established harmonized surveillance requirements across member states. The European Food Safety Authority publishes annual integrated analyses of antimicrobial resistance data spanning human medicine, veterinary medicine, and food production—a level of cross-sector integration that has no direct equivalent in the United States.

Critically, the EU framework imposes resistance monitoring obligations at the production level, rather than relying solely on downstream retail sampling. This upstream surveillance approach captures resistance patterns before they are diluted through the processing and distribution chain, providing more actionable data for regulatory intervention.

The United States has no equivalent to the EU's prohibition on prophylactic antibiotic use, no binding cross-sector resistance surveillance mandate, and no regulatory requirement for producers to report resistance data as a condition of continued market participation.

Toward a Unified Surveillance Architecture

Addressing these gaps requires action across several dimensions. First, NARMS should be substantially expanded in scope, incorporating comprehensive resistance gene surveillance—including mobile genetic elements—alongside its existing pathogen-specific monitoring. Second, the FDA and USDA should establish a formal joint surveillance protocol with binding data-sharing requirements, eliminating the jurisdictional discontinuity that currently allows resistance trends to develop in regulatory blind spots.

Third, large-scale commercial livestock operations should be subject to mandatory internal resistance monitoring with public reporting requirements, analogous to the environmental monitoring obligations imposed on other industries that generate externalities with documented public health consequences. The current voluntary framework is insufficient given the demonstrated scale of the resistance burden.

Fourth, the FDA should revisit the scope of permitted antibiotic uses in food animals, with particular attention to prophylactic applications that involve medically important antimicrobial classes. The scientific basis for more restrictive standards exists; what is required is regulatory alignment with that evidence base.

Antimicrobial resistance does not respect the administrative boundaries between agricultural policy and public health. A surveillance system that does not account for that reality is not merely incomplete—it is structurally inadequate for the challenge it faces.